Abstract
Overview
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic
stem cell disorders. With a forecast incidence of 36,769 across the seven
major markets in 2007, they are one of the most common hematological
malignancies. Currently, the only potentially curative option is hematopoietic
stem cell transplantation but this is only suitable for a small subset of
patients.
Scope
- MDS epidemiology, disease diagnosis and overview of current treatment
options
- Remaining unmet needs in the treatment of MDS
- Research and analysis of the MDS pipeline with in-depth clinical
assessment of Phase III candidates
- Stakeholder opinions based on qualitative interviews with key opinion
leaders from the US and EU
Report Highlights
Patients' old age and associated co-morbidities often prohibit the use of
high-intensity therapies such as hematopoietic stem cell transplantation.
Therefore, most patients rely on supportive care and low-intensity therapies
for the management of the disease.
While low-intensity therapies such as Vidaza, Dacogen and Revlimid have
improved patient outcomes, higher-risk MDS remains a disease with poor
prognosis. Therefore, there is a great need for more effective drugs with
favorable toxicity profiles to improve patient survival and quality of life.
Recent approvals have spurred interest in MDS but this has yet to be
translated into considerable R&D efforts in the field. There is only one drug
in Phase III development, Schering-Plough' s Sarasar (lonafarnib). This
molecular targeted therapy is unlikely to offer any significant improvements
over existing therapies.
Reasons to Purchase
- Gain an insight into the current classification systems and the
epidemiology trends for MDS
- Identify the limitations of current MDS treatment options and consider the
remaining unmet needs
- Acquire a detailed appreciation and impartial perspective of the MDS
pipeline
| 
View Cart
